IXHL Key Statistics, Chart & Performance
The current stock price of IXHL is 0.358 USD. In the past month the price decreased by -9.73%. In the past year, price decreased by -81.64%.
IXHL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.42B |
Related stock screener links
About IXHL
Company Profile
Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Company Info
INCANNEX HEALTHCARE INC
8 Century Circuit, Ste. 105, Norwest
New York City NEW SOUTH WALES AU
Employees: 12
Phone: 61409840786
INCANNEX HEALTHCARE INC / IXHL FAQ
What does INCANNEX HEALTHCARE INC do?
Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Can you provide the latest stock price for INCANNEX HEALTHCARE INC?
The current stock price of IXHL is 0.358 USD. The price decreased by -0.58% in the last trading session.
Does IXHL stock pay dividends?
IXHL does not pay a dividend.
What is the ChartMill rating of INCANNEX HEALTHCARE INC stock?
IXHL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of INCANNEX HEALTHCARE INC (IXHL) based on its PE ratio?
INCANNEX HEALTHCARE INC (IXHL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).
Should I buy IXHL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IXHL.
Can you provide the upcoming earnings date for INCANNEX HEALTHCARE INC?
INCANNEX HEALTHCARE INC (IXHL) will report earnings on 2026-02-12.
IXHL Technical Analysis
IXHL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IXHL. IXHL has a great financial health rating, but its profitability evaluates not so good.
IXHL Financial Highlights
Over the last trailing twelve months IXHL reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by -19.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.56% | ||
| ROE | -60.88% | ||
| Debt/Equity | 0 |
IXHL Forecast & Estimates
For the next year, analysts expect an EPS growth of 97.08% and a revenue growth -100% for IXHL